Imunon, Inc. (IMNN) Executive Chair receives 43,821 stock options

Rhea-AI Filing Summary

Imunon, Inc. Executive Chairman Michael H. Tardugno received a grant of stock options for 43,821 shares on January 2, 2026. The options give him the right to buy Imunon common stock at an exercise price of $3.95 per share, which the disclosure notes was the closing price of the stock on the grant date.

The options were granted at no cash cost for the derivative security itself and expire on January 2, 2036. They vest over time, with one-half vesting on the grant date, one-quarter on the one-year anniversary of the grant, and the remaining one-quarter on the second anniversary. Following this grant, Tardugno beneficially owns 43,821 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardugno Michael H

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NJ 08648

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman of Board

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.95(1)	01/02/2026		A		43,821		01/02/2026(2)	01/02/2036	Common Stock	43,821	$0	43,821	D

Explanation of Responses:

1. Represents the closing price of Imunon, Inc. Common Stock on the date of the grant

2. The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

	/s/ Susan Eylward, Attorney-in-Fact for Michael Tardugno	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Imunon (IMNN) report for Michael H. Tardugno?

Imunon reported that Executive Chairman Michael H. Tardugno received a grant of 43,821 stock options on January 2, 2026, giving him the right to purchase Imunon common stock under the company’s equity compensation arrangements.

What is the exercise price of the new Imunon (IMNN) stock options?

The stock options granted to Michael H. Tardugno have an exercise price of $3.95 per share, which is stated to represent the closing price of Imunon common stock on the grant date.

How do the stock options granted to Imunon (IMNN) Executive Chairman vest?

The options vest in stages: one-half of the grant vests on the date of grant, one-quarter vests on the one-year anniversary of the grant, and the final one-quarter vests on the second-year anniversary of the grant.

When do Michael H. Tardugno’s Imunon (IMNN) stock options expire?

The stock options granted on January 2, 2026 to Michael H. Tardugno are scheduled to expire on January 2, 2036, if they are not exercised earlier.

How many Imunon (IMNN) derivative securities does Michael H. Tardugno own after this grant?

After the reported transaction, Michael H. Tardugno beneficially owns 43,821 stock options directly, as disclosed in the filing.

Did Michael H. Tardugno pay anything for the Imunon (IMNN) stock option grant itself?

The filing lists the price of the derivative security as $0, indicating the options were granted without a cash payment for the option itself, while the $3.95 per share exercise price applies if he chooses to buy the underlying stock.